Biosimilars may appear at first glance to be a Wild West for patents, but guidance just out from the U.S. Patent and Trademark Office shows that adding “specific claim parameters” is the key for innovator biologic companies to establish enforceable protections for their products, a leading patent attorney says.
USPTO issued the document July 3, following the U.S. Supreme Court’s March 20 ruling in Mayo Collaborative Services v.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?